Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Autodesk Inc (ADSK) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Autodesk IncTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Autodesk Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Autodesk Inc trades at $247.55 (market cap $53.12B), while Ginkgo Bioworks Holdings Inc trades at $7.43 (market cap $505.73M). The key difference: Autodesk Inc is far larger — about 105× Ginkgo Bioworks Holdings Inc's market cap, and Autodesk Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.

ADSKDNA
Market Cap
$53.12B$505.73M
Sector
TechnologyHealth
52-Week High
$326.79$16.14
52-Week Low
$187.72$5.48
Enterprise Value
$52.92B$607.68M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Autodesk Inc

Autodesk (ADSK) trades at $247.39, down 3.39% in the latest session, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The stock shows a bullish technical trend with moving averages supporting upside momentum, while RSI levels indicate potential overbought conditions. Recent financial performance demonstrates expanding profit margins and healthy cash flow generation, supported by the company's dominant position in design software markets.

The outlook remains positive with analyst consensus favoring continued growth, though elevated valuation multiples and competitive pressures present risks. Upside potential exists toward the $302.23 consensus price target, supported by strong institutional backing and strategic AI investments. Key risks include market volatility and execution challenges in maintaining premium valuation levels.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Returns comparison

Trailing returns across standard periods

About Autodesk Inc

Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.

Read more on ADSK

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA